Title21 Health Solutions, a portfolio company specialising in supporting life science regulatory needs, has joined the Blood and Cells Advocacy Roster (BCAR), an industry collaboration focused on the importance of blood and cell therapies.
Established in 2024, BCAR is an international body that aims to emphasise the importance of the blood industry and improve patient access to advanced therapies. Community blood centres supply almost 60% of the US’ blood supply, and around 25% of Canada’s, with more than 700 donor facilities serving over 1,100 communities. Many of these centres are now leveraging their expertise to provide specialised blood products for cell therapies, increasing nationwide access to medical innovations.
Michelle Boxall, founder of BCAR, said: “As innovators in regulatory and compliance software working in the blood industry, Title21 brings a vital technology perspective to our collective voice.”
The steering committee for BCAR includes members from America’s Blood Centers (ABC), Association for the Advancement of Blood & Biotherapies (AABB), BioBridge Global, Blood Centers of America (BCA), Terumo Blood and Cell Technologies, Title21 and Vitalant.
“Blood is not only foundational to healthcare, it is a critical enabler of innovation in cell and gene therapies,” Jonathan Wofford, chief commercial officer at Title21, said. “By combining robust technology with the expertise of blood centres, we believe we can help streamline processes, strengthen compliance and ultimately improve patient outcomes.”
Title21 was founded in 2001. It is a portfolio company of Archimed, a leading growth equity enterprise.
